All insightsSeptember 25, 2026

MedTech Industry Pulse: September 2026 Regulatory and Digital Health Roundup

September brought consequential FDA robotics and PMA submission updates, a major Medicare TAVR coverage decision, evolving AI oversight, revised EU IVDR classification guidance and signals of UK medical-device reform.

September 2026 brought a concentrated set of developments for medical-device, digital-health and diagnostics teams. The month’s central signal was not a single new rule. It was the growing connection between product design, regulatory evidence, Medicare coverage, artificial-intelligence governance and market-specific execution.

FDA advanced its expectations for robotically assisted surgery and electronic PMA submissions. CMS revised national coverage for transcatheter aortic valve replacement while seeking feedback on a faster coverage route for certain breakthrough devices. European regulators clarified an important IVDR classification rule, and the United Kingdom continued laying the groundwork for a more adaptable medical-device framework.

For MedTech leaders, the practical message is clear: authorization, coverage and adoption must be planned as one connected pathway. A technically strong device can still lose time if its submission architecture, evidence plan, reimbursement strategy or market sequencing is developed too late.

US regulatory focus: robotic surgery moves into sharper view

On September 25, FDA announced a new draft guidance on premarket submissions for robotically assisted surgical devices. The document is intended to clarify the information manufacturers should include when seeking authorization for these systems, an increasingly important category as robotic platforms add advanced software, automation, connectivity and remote capabilities.

The draft matters beyond conventional surgical robots. It reflects the questions regulators are asking whenever software and hardware share control of a high-risk clinical task: What functions are automated? Which decisions remain with the clinician? How does the system communicate state, limitations and faults? What happens when connectivity, sensing or an accessory fails? How were the user interface and foreseeable misuse evaluated?

FDA is accepting comments through November 24, 2026. Developers should compare current design controls and submission plans against the proposed framework. The Federal Register notice for the robotically assisted surgical-device draft guidance provides the official docket and deadlines.

Teams developing autonomous or remotely operated features should treat benefit-risk evidence as a system-level question. Clinical performance alone may not capture risks created by latency, loss of communication, software updates, cybersecurity events or unclear handoffs between a person and an automated function. Those issues need to be visible in risk management, verification, validation, human-factors work and post-market monitoring.

PMA submissions are moving toward a structured electronic template

FDA also published a draft guidance for an electronic submission template for Premarket Approval applications on September 18. The proposed approach is designed to standardize how PMA content is assembled and submitted, building on FDA’s broader move toward structured electronic submissions.

For Class III device teams, this is more than an administrative formatting change. Structured templates can expose missing information earlier, improve consistency across submission modules and make cross-functional ownership clearer. They can also create rework when clinical, engineering, quality and regulatory records were not organized around a common evidence architecture from the start.

Manufacturers preparing an original PMA, supplement or future filing should map their document-production process against the draft template now. The official PMA electronic-submission-template notice lists a November 17, 2026 comment deadline.

The operational lesson is to make submission readiness a product-development discipline. Traceability from user needs to design inputs, risks, verification, validation, labeling and clinical evidence should not depend on a final document-assembly sprint.

AI-enabled devices: lifecycle oversight remains the direction of travel

FDA refreshed its central resource for artificial intelligence-enabled medical devices in September. The page emphasizes the agency’s total-product-lifecycle and risk-based approach while continuing to provide access to its AI-enabled device list.

That lifecycle framing is significant. An AI-enabled device is not fully characterized by the performance of one locked model at one point in time. Data provenance, clinically relevant subgroup performance, human oversight, transparency, cybersecurity, update controls and post-market monitoring all influence whether performance remains safe and useful in real deployment.

The September activity follows FDA’s August request for public feedback on generative AI-enabled medical devices. The FDA announcement on generative AI-enabled devices identifies issues including rapidly evolving models and the need for an appropriate regulatory approach.

Companies should avoid adding a general-purpose model to a medical workflow without first defining the regulated function, intended user, input boundaries, acceptable outputs, escalation path and change-control strategy. The product claim determines the evidence burden. The CAHIR PCCP guide and 21 CFR Part 11 and electronic records guide can help teams structure change planning, records and controls before submission pressure begins.

Medicare coverage: CMS revises the national TAVR policy

On September 10, CMS issued its final decision memo for transcatheter aortic valve replacement. The revised national coverage policy removes Coverage with Evidence Development for treatment of symptomatic severe aortic stenosis, extends CED-based coverage to specified uses in asymptomatic severe aortic stenosis and updates requirements involving heart teams, operators and facilities.

This is a meaningful market-access development because coverage conditions influence much more than payment. They shape eligible patients, participating sites, clinical evidence generation, referral pathways and the operational burden placed on hospitals. The CMS final TAVR decision memo contains the controlling coverage details and implementation conditions.

The broader lesson applies across device categories: FDA authorization and Medicare coverage answer different questions. FDA evaluates whether a device is safe and effective for its intended use. CMS considers whether an item or service is reasonable and necessary for Medicare beneficiaries and under what conditions it should be covered. Evidence strategies should anticipate both decisions rather than treating reimbursement as a post-clearance task.

RAPID coverage could narrow—but not eliminate—the authorization-to-payment gap

CMS’s proposed Regulatory Alignment for Predictable and Immediate Device coverage pathway remained an important live issue in September, with comments due October 13, 2026. RAPID is intended to improve coordination between FDA authorization and Medicare national coverage for qualifying breakthrough devices.

The proposal signals recognition of a persistent MedTech problem: a device may obtain authorization but still face a long and uncertain path to coverage. Faster procedural alignment could reduce part of that delay. It would not remove the need for a strong Medicare evidence package, appropriate coding, a viable payment level, site readiness or convincing hospital economics.

Device sponsors should review the official RAPID coverage proposal and test their plans against three questions: Is the Medicare population clearly defined? Does the evidence address outcomes that matter to beneficiaries and clinicians? Can providers adopt the technology under the expected payment and workflow conditions?

CAHIR’s medical device market-access guide and MedTech Compass connect regulatory milestones with coverage, payment, competitive intelligence and geographic prioritization.

Europe: revised IVDR classification guidance clarifies Rule 7

On September 9, the Medical Device Coordination Group published Revision 5 of MDCG 2020-16, its guidance on classification rules for in vitro diagnostic medical devices under the IVDR. The revision clarifies the rationale for Rule 7 and updates classification examples.

Classification determines the conformity-assessment route, notified-body involvement and evidence expectations for an IVD. A mistaken assumption can therefore affect development cost, documentation, review timelines and launch sequencing. IVD manufacturers should review the updated examples against intended purpose, specimen type, analyte, user and the consequence of an incorrect result.

The European Commission’s notice for MDCG 2020-16 Revision 5 links to the revised guidance. Teams should document why a rule applies, why competing rules do not and how the selected classification aligns with claims and technical documentation.

This update also reinforces a wider global-pathway principle: classification is not a label applied after development. It is an early strategic decision that should guide evidence, quality planning and commercial timelines.

United Kingdom: reform points toward a more adaptable device framework

The UK government published a September 9 fact sheet describing medical-device and medicines reforms proposed through the Health Bill. The measures are intended to give regulators tools to update requirements more efficiently and include enabling provisions related to a future medical-device licensing approach.

These provisions do not themselves create an immediate new route to market. Further policy development and consultation would be required. Still, manufacturers planning a Great Britain launch should monitor the direction closely because future licensing, recognition and oversight arrangements could change market-entry assumptions.

The official Health Bill regulatory-reforms fact sheet explains the proposed powers. On September 21, MHRA also highlighted its Regulatory Advice Service for medical devices, which offers manufacturers a route to seek advice on regulatory questions.

For global teams, the key is to maintain separate US, EU and UK pathway assumptions. Shared evidence can create efficiency, but classification, claims, submission mechanics and post-market obligations cannot be treated as interchangeable.

What MedTech teams should do next

First, review robotic, AI-enabled and connected-device development plans for explicit human oversight, failure handling, cybersecurity and post-market monitoring. These controls should be traceable, not implied.

Second, build submission structure early. PMA and other premarket teams should organize evidence so that a structured electronic template does not expose avoidable gaps late in the program.

Third, connect the regulatory and reimbursement workstreams. Coverage conditions, coding, payment and hospital implementation should influence clinical endpoints and evidence collection before authorization.

Fourth, revisit European IVD classifications where Rule 7 may apply, and document the rationale using the revised MDCG examples.

Finally, maintain a jurisdiction-specific change watch. September’s developments show why a global launch plan needs active assumptions for FDA, CMS, EU IVDR and MHRA rather than one static regulatory timeline.

The September signal

The September 2026 MedTech pulse is a shift toward connected execution. Robotics guidance links software behavior to human factors and system safety. Electronic PMA templates link submission quality to evidence architecture. AI oversight links authorization to lifecycle controls. Medicare decisions link clinical evidence to coverage conditions. European and UK updates link classification and market access to evolving regional frameworks.

The teams best positioned for 2027 will not simply react to each document. They will build one operating model that connects product strategy, regulatory evidence, quality, reimbursement and post-market intelligence.

Explore the CAHIR MedTech product suite for regulatory execution and global medical-device market intelligence. Use MedTech Copilot to structure regulatory and quality work, and MedTech Compass to evaluate reimbursement, competitive position and market priorities.